-
Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma
Vega, G., Morillo, D., Riedhammer, C., Smits, F., Bag, A., Julian, K., Gomis, N. T., Gaisan, C. M., Bermudez, M. A., Shah, M. R., Mohyuddin, G. R., Dhakal, B., Rasche, L., Schinke, C., D'Souza, A., Szabo, A., van de Donk, N. W. C. J., Chakraborty, R. & Mohan, M., 1 Jun 2026, In: HemaSphere. 10, 6, e70396.Research output: Contribution to Journal › Comment / Letter to the editor › Academic
-
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
Groen, K., Smits, F., Nasserinejad, K., Levin, M.-D., Regelink, J. C., Timmers, G.-J., de Waal, E. G. M., Westerman, M., Velders, G. A., de Heer, K., Leys, R. B. L., van Kampen, R. J. W., Stege, C. A. M., Seefat, M. R., Nijhof, I. S., van der Spek, E., Klein, S. K., van de Donk, N. W. C. J., Ypma, P. F. & Zweegman, S., 1 Dec 2025, In: HemaSphere. 9, 12, e70268.Research output: Contribution to Journal › Comment / Letter to the editor › Academic
-
Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial
Smits, F., Groen, K., Levin, M.-D., Stege, C. A. M., van Kampen, R., van der Spek, E., Nijhof, I., Bilgin, Y. M., Thielen, N., Ludwig, I., de Waal, E. G. M., Sandberg, Y., Kentos, A., Timmers, G.-J., Regelink, J. C., Westerman, M., de Heer, K., Vekemans, M.-C., Durdu-Rayman, N. & HOVON 143 Study Group, 25 Nov 2025, In: Blood. 9, 22, p. 5828-5836 9 p.Research output: Contribution to Journal › Article › Academic › peer-review
- All publications
